Taisho Pharmaceutical Holdings Past Earnings Performance
Past criteria checks 0/6
Taisho Pharmaceutical Holdings's earnings have been declining at an average annual rate of -25.1%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 2.9% per year. Taisho Pharmaceutical Holdings's return on equity is 1.3%, and it has net margins of 2.6%.
Key information
-25.1%
Earnings growth rate
-25.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 2.9% |
| Return on equity | 1.3% |
| Net Margin | 2.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Taisho Pharmaceutical Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 320,385 | 8,421 | 143,526 | 20,727 |
| 30 Sep 23 | 319,960 | 15,570 | 138,812 | 20,727 |
| 30 Jun 23 | 313,114 | 17,609 | 136,760 | 20,727 |
| 31 Mar 23 | 301,381 | 18,997 | 134,104 | 20,727 |
| 31 Dec 22 | 295,821 | 25,047 | 131,886 | 19,366 |
| 30 Sep 22 | 282,560 | 21,091 | 131,638 | 19,366 |
| 30 Jun 22 | 273,388 | 17,694 | 133,209 | 19,366 |
| 31 Mar 22 | 268,203 | 13,122 | 133,722 | 19,366 |
| 31 Dec 21 | 267,731 | 8,055 | 135,036 | 20,251 |
| 30 Sep 21 | 266,241 | 4,930 | 134,701 | 20,251 |
| 30 Jun 21 | 270,841 | 8,431 | 134,995 | 20,251 |
| 31 Mar 21 | 281,980 | 13,316 | 135,770 | 20,251 |
| 31 Dec 20 | 291,489 | 16,837 | 135,082 | 22,876 |
| 30 Sep 20 | 302,219 | 16,846 | 140,066 | 22,876 |
| 30 Jun 20 | 303,290 | 15,589 | 140,904 | 22,876 |
| 31 Mar 20 | 288,527 | 20,531 | 136,047 | 22,876 |
| 31 Dec 19 | 272,993 | 15,124 | 132,217 | 20,801 |
| 30 Sep 19 | 264,268 | 21,138 | 123,100 | 20,801 |
| 30 Jun 19 | 260,063 | 45,910 | 118,742 | 20,801 |
| 31 Mar 19 | 261,551 | 48,593 | 118,150 | 20,801 |
| 31 Dec 18 | 264,190 | 56,614 | 115,417 | 21,150 |
| 30 Sep 18 | 270,953 | 62,097 | 118,787 | 21,150 |
| 30 Jun 18 | 273,308 | 39,834 | 119,888 | 21,150 |
| 31 Mar 18 | 280,092 | 31,679 | 124,857 | 21,150 |
| 31 Dec 17 | 279,140 | 31,574 | 125,339 | 21,260 |
| 30 Sep 17 | 277,396 | 27,298 | 125,702 | 21,260 |
| 30 Jun 17 | 278,874 | 27,370 | 127,056 | 21,260 |
| 31 Mar 17 | 279,773 | 28,781 | 125,000 | 21,260 |
| 31 Dec 16 | 281,588 | 27,438 | 124,306 | 21,768 |
| 30 Sep 16 | 285,158 | 24,691 | 124,665 | 21,768 |
| 30 Jun 16 | 290,354 | 24,732 | 124,240 | 21,768 |
| 31 Mar 16 | 290,135 | 22,473 | 126,167 | 21,768 |
| 31 Dec 15 | 293,717 | 23,594 | 126,166 | 21,554 |
| 30 Sep 15 | 294,677 | 23,217 | 127,422 | 21,554 |
| 30 Jun 15 | 291,339 | 22,556 | 148,809 | 0 |
| 31 Mar 15 | 290,498 | 24,529 | 124,720 | 21,554 |
| 31 Dec 14 | 289,777 | 24,493 | 126,876 | 21,874 |
| 30 Sep 14 | 293,199 | 28,769 | 124,443 | 21,874 |
| 30 Jun 14 | 296,150 | 31,940 | 122,246 | 21,874 |
| 31 Mar 14 | 295,958 | 32,693 | 121,135 | 21,875 |
| 31 Dec 13 | 292,838 | 32,311 | 117,998 | 23,331 |
| 30 Sep 13 | 289,779 | 30,170 | 118,797 | 23,331 |
| 30 Jun 13 | 285,573 | 26,139 | 118,372 | 23,331 |
Quality Earnings: TAIP.Y has a large one-off loss of ¥7.9B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: TAIP.Y's current net profit margins (2.6%) are lower than last year (8.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TAIP.Y's earnings have declined by 25.1% per year over the past 5 years.
Accelerating Growth: TAIP.Y's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: TAIP.Y had negative earnings growth (-66.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-13.2%).
Return on Equity
High ROE: TAIP.Y's Return on Equity (1.3%) is considered low.